Jean-Thomas Vilquin

Jean-Thomas Vilquin

Auto-generated profile, based on publicly available information

Jean-Thomas Vilquin

UPMC UM 76, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in The Lancet
Verified
Journal Article
Closed access
PMPhilippe Menasché
Philippe Menasché
AHAlbert Hagege
Albert Hagege
MSMarcio Scorsin
Marcio Scorsin
BPBruno Pouzet
Bruno Pouzet
MDMichel Desnos
Michel Desnos
JMJean-Pierre Marolleau
Jean-Pierre Marolleau

1 April 2003 in JACC
Verified
Journal Article
Closed access
PMPhilippe Menasché
Philippe Menasché
AHAlbert Hagege
Albert Hagege
JVJean-Thomas Vilquin
Jean-Thomas Vilquin
MDMichel Desnos
Michel Desnos
EAEric Abergel
Eric Abergel
DDDenis Duboc
Denis Duboc

4 March 2008 in Circulation
Verified
Journal Article
Closed access
PDF file
PMPhilippe Menasché
Philippe Menasché
OAOttavio Alfieri
Ottavio Alfieri
SJStefan Janssens
Stefan Janssens
WMWilliam McKenna
William McKenna
HRHermann Reichenspurner
Hermann Reichenspurner
AHAlbert A. Hagège
Albert A. Hagège
Background— Phase I clinical studies have demonstrated the feasibility of implanting autologous skeletal myoblasts in postinfarction scars. However, they have failed to determine whether this procedure was functionally effective and arrhythmogenic. Methods and Results— This multicenter, randomized, placebo-controlled, double-blind study included patients with left ventricular (LV) dysfunction (ejection fraction ≤35%), myocardial infarction, and indication for coronary surgery. Each patient received either cells grown from a skeletal muscle biopsy or a placebo solution injected in and around the scar. All patients received an implantable cardioverter-defibrillator. The primary efficacy end points were the 6-month changes in global and regional LV function assessed by echocardiography. The safety end points comprised a composite index of major cardiac adverse events and ventricular arrhythmias. Ninety-seven patients received myoblasts (400 or 800 million; n=33 and n=34, respectively) or the placebo (n=30). Myoblast transfer did not improve regional or global LV function beyond that seen in control patients. The absolute change in ejection fraction (median [interquartile range]) between 6 months and baseline was 4.4% (0.2; 7.3), 3.4% (−0.3; 12.4), and 5.2% (−4.4; 11.0) in the placebo, low-dose, and high-dose groups, respectively ( P =0.95). However, the high-dose cell group demonstrated a significant decrease in LV volumes compared with the placebo group. Despite a higher number of arrhythmic events in the myoblast-treated patients, the 6-month rates of major cardiac adverse events and of ventricular arrhythmias did not differ significantly between the pooled treatment and placebo groups. Conclusions— Myoblast injections combined with coronary surgery in patients with depressed LV function failed to improve echocardiographic heart function. The increased number of early postoperative arrhythmic events after myoblast transplantation, as well as the capability of high-dose injections to revert LV remodeling, warrants further investigation.

12 June 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
BLBertrand Léobon
Bertrand Léobon
IGIsabelle Garcin
Isabelle Garcin
PMPhilippe Menasché
Philippe Menasché
JVJean-Thomas Vilquin
Jean-Thomas Vilquin
EAEtienne Audinat
Etienne Audinat
SCSerge Charpak
Serge Charpak
Survival and differentiation of myogenic cells grafted into infarcted myocardium have raised the hope that cell transplantation becomes a new therapy for cardiovascular diseases. The approach was further supported by transplantation of skeletal myoblasts, which was shown to improve cardiac performance in several animal species. Despite the success of myoblast transplantation and its recent trial in human, the mechanism responsible for the functional improvement remains unclear. Here, we used intracellular recordings coupled to video and fluorescence microscopy to establish whether myoblasts, genetically labeled with enhanced GFP and transplanted into rat infarcted myocardium, retain excitable and contractile properties, and participate actively to cardiac function. Our results indicate that grafted myoblasts differentiate into peculiar hyperexcitable myotubes with a contractile activity fully independent of neighboring cardiomyocytes. We conclude that mechanisms other than electromechanical coupling between grafted and host cells are involved in the improvement of cardiac function.

1 June 2000 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MSMarcio Scorsin
Marcio Scorsin
AHAlbert Hagege
Albert Hagege
JVJean-Thomas Vilquin
Jean-Thomas Vilquin
MFMarc Fiszman
Marc Fiszman
FMFrançoise Marotte
Françoise Marotte
PMPhilippe Menasché
Philippe Menasché

1 February 2003 in The Lancet
Verified
Journal Article
Closed access
AHAlbert Hagege
Albert Hagege
CCClaire Carrion
Claire Carrion
PMPhilippe Menasché
Philippe Menasché
JVJean-Thomas Vilquin
Jean-Thomas Vilquin
DDDenis Duboc
Denis Duboc
PBPatrick Bruneval
Patrick Bruneval